Recent developments to share with you

School of Pharmacy, China Pharmaceutical University Holds Plaque Presentation Ceremony with Nanjing Kangchuanji for Graduate Employment Base

2023-04-03


At the beginning of the event, Yin Lifang, General Manager of our company, led the visitors on a “Welcome to Kangchuanji” tour, giving a detailed introduction to the company’s development history, operational scale, talent pool, and main business areas. Subsequently, Zhang Shiying, Secretary of the Party Committee of the School of Pharmacy, introduced the school’s basic situation in terms of its history, number of faculty and students, and research capabilities. Meng Xiangkang, Deputy Secretary of the Party Committee of the School, shared the scale of the 2023 graduating class and the school’s current overall employment situation. Both sides conducted in-depth discussions on industry-university-research collaboration, student internships and apprenticeships, and graduate employment, further clarifying their intentions and exploring ways to cooperate.

On the morning of March 23, a delegation from the School of Pharmacy, China Pharmaceutical University visited our company for an exchange and held the “Graduate Employment Base of the School of Pharmacy, China Pharmaceutical University” plaque presentation ceremony. Attendees included Zhang Shiying (Secretary of the School’s Party Committee), Meng Xiangkang (Deputy Secretary), and graduation class advisors from the school, as well as Yin Lifang (General Manager of our company), Zhu Chunli (Deputy General Manager), Zhao Gang (Deputy General Manager), and Huang Huiwen (Deputy General Manager).

After the exchange, Secretary Zhang Shiying and General Manager Yin Lifang, as representatives of both sides, held the plaque presentation ceremony for the School’s Graduate Employment Base.

Following the ceremony, Deputy General Manager Zhu Chunli led the visitors on a tour of our laboratory, providing a detailed introduction to its scale and equipment.

This event aims to make full use of the universityenterprise cooperation platform. Adhering to the principles of mutual collaboration, mutual benefit, and shared development, both sides will continue to expand their cooperation channels, promote joint growth, provide students with more and better learning, practice, and employment opportunities, and inject new vitality into the company. We look forward to extending our cooperation into broader and deeper areas.

Keywords:

Related information

Bountiful Results | January–July 2026: Kangchuanji Pharmaceutical, in collaboration with multiple pharmaceutical companies, secured approval or passed the evaluation for 15 product specifications.

From January to July 2026, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd., leveraging its deep-rooted pharmaceutical R&D expertise and mature end-to-end CDMO capabilities, has provided robust support for the innovative R&D and commercialization of its partner companies, achieving further regulatory‑review milestones in collaboration with multiple partners. According to the NMPA’s public announcement of drug approval documents, a total of 12 drug products (covering 15 specifications) have been successfully approved or passed consistency evaluation, demonstrating significant results in translating innovative research into tangible outcomes.

2026-08-04

CDE Announcement: Updated Guidelines for Pediatric Medicines! “Technical Guidance on the Application of Physiologically Based Pharmacokinetic Models in Drug Development for Pediatric Populations (Draft for Public Comment)”

On August 17, the CDE released a draft of the “Technical Guidance for the Application of Physiologically Based Pharmacokinetic Models in Pediatric Drug Development” for public comment.

2024-10-27

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03